Omid Yazdani

Omid Yazdani

Auto-generated profile, based on publicly available information

Omid Yazdani

Research, Institute for Gastroenterology and Liver Diseases Shahid Beheshti University of Medical Sciences Tehran Iran

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2022 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
MJMohammadsaleh Jahangir
Mohammadsaleh Jahangir
OYOmid Yazdani
Omid Yazdani
MKMohammad saeed Kahrizi
Mohammad saeed Kahrizi
SSSara Soltanzadeh
Sara Soltanzadeh
HJHamidreza Javididashtbayaz
Hamidreza Javididashtbayaz
RERomina Esbati
Romina Esbati
Programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) blockade therapy has become a game-changing therapeutic approach revolutionizing the treatment setting of human malignancies, such as renal cell carcinoma (RCC). Despite the remarkable clinical activity of anti-PD-1 or anti-PD-L1 monoclonal antibodies, only a small portion of patients exhibit a positive response to PD-1/PD-L1 blockade therapy, and the primary or acquired resistance might ultimately favor cancer development in patients with clinical responses. In light of this, recent reports have signified that the addition of other therapeutic modalities to PD-1/PD-L1 blockade therapy might improve clinical responses in advanced RCC patients. Until, combination therapy with PD-1/PD-L1 blockade therapy plus cytotoxic T lymphocyte antigen 4 (CTLA-4) inhibitor (ipilimumab) or various vascular endothelial growth factor receptors (VEGFRs) inhibitors axitinib, such as axitinib and cabozantinib, has been approved by the United States Food and Drug Administration (FDA) as first-line treatment for metastatic RCC. In the present review, we have focused on the therapeutic benefits of the PD-1/PD-L1 blockade therapy as a single agent or in combination with other conventional or innovative targeted therapies in RCC patients. We also offer a glimpse into the well-determined prognostic factor associated with the clinical response of RCC patients to PD-1/PD-L1 blockade therapy.

1 January 2022 in BioMed Research International
Verified
Journal Article
Open access
PDF file
HHHamidreza Hatamabadi
Hamidreza Hatamabadi
TSTahereh Sabaghian
Tahereh Sabaghian
ASAmir Sadeghi
Amir Sadeghi
KHKamran Heidari
Kamran Heidari
SSSeyed Amir Ahmad Safavi-Naini
Seyed Amir Ahmad Safavi-Naini
Amirhossein SahebkarAmirhossein Sahebkar
Amirhossein Sahebkar
Background. The outbreak of coronavirus disease 2019 (COVID‐19) dates back to December 2019 in China. Iran has been among the most prone countries to the virus. The aim of this study was to report demographics, clinical data, and their association with death and CFR. Methods. This observational cohort study was performed from 20th March 2020 to 18th March 2021 in three tertiary educational hospitals in Tehran, Iran. All patients were admitted based on the WHO, CDC, and Iran’s National Guidelines. Their information was recorded in their medical files. Multivariable analysis was performed to assess demographics, clinical profile, outcomes of disease, and finding the predictors of death due to COVID‐19. Results. Of all 5318 participants, the median age was 60.0 years, and 57.2% of patients were male. The most significant comorbidities were hypertension and diabetes mellitus. Cough, dyspnea, and fever were the most dominant symptoms. Results showed that ICU admission, elderly age, decreased consciousness, low BMI, HTN, IHD, CVA, dialysis, intubation, Alzheimer disease, blood injection, injection of platelets or FFP, and high number of comorbidities were associated with a higher risk of death related to COVID‐19. The trend of CFR was increasing (WPC: 1.86) during weeks 25 to 51. Conclusions. Accurate detection of predictors of poor outcomes helps healthcare providers in stratifying patients, based on their risk factors and healthcare requirements to improve their survival chance.

23 February 2024 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
HMHossein Mohebbi
Hossein Mohebbi
RERomina Esbati
Romina Esbati
RHRan Abdalsalam Hamid
Ran Abdalsalam Hamid
RARoozbeh Akhavanfar
Roozbeh Akhavanfar
URUsama Kadem Radi
Usama Kadem Radi
OYOmid Yazdani
Omid Yazdani

5 March 2025 in Health Science Reports
Verified
Journal Article
Open access
ASAryan Salahi‐Niri
Aryan Salahi‐Niri
PZPaniz Zarand
Paniz Zarand
NMNegar Mansouri
Negar Mansouri
PRParvaneh Rastgou
Parvaneh Rastgou
OYOmid Yazdani
Omid Yazdani
SSSeyed Amir Ahmad Safavi-Naini
Seyed Amir Ahmad Safavi-Naini
Background and Aims: Pancreatic cancer is an aggressive malignancy with poor prognosis and limited treatment options. Chemotherapy remains a primary therapeutic approach, but patient responses vary significantly, emphasizing the need for reliable biomarkers. This review explores the potential role of proliferative markers, including Ki‐67, PCNA, Cyclin D1, and PHH3, as predictive and prognostic indicators in pancreatic cancer management, aiming to enhance personalized treatment strategies.Methods: We conducted a narrative review by searching Scopus, PubMed, and Google Scholar for studies focusing on Ki‐67, PCNA, Cyclin D1, and PHH3 in relation to pancreatic cancer and chemotherapy. The literature was reviewed to evaluate the role of these markers in predicting chemotherapy response, tumor progression, and overall patient survival.Results: The review highlights the clinical significance of these markers. Ki‐67 and PCNA are associated with cell proliferation, while Cyclin D1 regulates cell cycle progression and PHH3 is linked to mitotic activity. High expression levels of these markers often correlate with increased tumor aggressiveness and poorer patient outcomes. Moreover, they show promise in predicting chemotherapy response, which can inform tailored therapeutic strategies. However, challenges remain, including standardization of detection methods and determination of optimal cutoff values.Conclusion: Proliferative markers such as Ki‐67, PCNA, Cyclin D1, and PHH3 hold potential as predictive and prognostic tools in pancreatic cancer management. Their integration into clinical practice could improve the accuracy of treatment decisions and enhance patient outcomes. Further research and validation are necessary to overcome existing challenges and optimize their application in personalized oncology.

21 November 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NANeda Azarpey
Neda Azarpey
SSShahrzad-Sadat Seyed-Bagher-Nazeri
Shahrzad-Sadat Seyed-Bagher-Nazeri
OYOmid Yazdani
Omid Yazdani
RERomina Esbati
Romina Esbati
PBParia Boustani
Paria Boustani
ZGZohre Ghasemi
Zohre Ghasemi
Background: The diagnosis of Meniere’s Disease (MD) presents significant challenges due to its complex symptomatology and the absence of definitive biomarkers. Advancements in MRI technology have spotlighted endolymphatic hydrops (EH) as a key pathological marker, necessitating a reevaluation of its diagnostic utility amidst the need for standardized and validated MRI-based grading scales. Methods: Our meta-analysis scrutinized the diagnostic efficacy of semi-quantitative MRI-based cochlear endolymphatic hydrops (EH) and perilymphatic enhancement (PLE) grading systems in delineating clinically relevant discriminations: “Spotting” the shift from normal or asymptomatic ears to possible/probable MD (pMD), “Confirming” the progression to definite MD (dMD), and “Establishing” the presence of dMD. A thorough literature search up to October 2023 resulted in 35 pertinent studies, forming the basis of our analysis through a bivariate mixed-effects regression model. Results: Using criteria from the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) and Barany Society, across varying thresholds and disease probabilities; the Establishment model at an EH grade 1 threshold revealed a sensitivity of 85.4% and a specificity of 82.7%. Adjusting the threshold to EH grade 2 results in a sensitivity increase to 92.1% (CI: 85.9–95.7) and a specificity decrease to 70.6% (CI: 64.5–76.1), with a DOR of 28.056 (CI: 14.917–52.770). The Confirmation model yields a DOR of 5.216, indicating a lower diagnostic accuracy. The Spotting model demonstrates a sensitivity of 48.3% (CI: 34.8–62.1) and a specificity of 88.0% (CI: 77.8–93.9), with a DOR of 6.882. The normal ears subgroup demonstrated a notably high specificity of 89.7%, while employing Nakashima’s criteria resulted in a reduced sensitivity of 74.9%, significantly diverging from other systems (p-value < 0.001). The PLE grading system showcased exceptional sensitivity of 98.4% (CI: 93.7–99.6, p-value < 0.001). Conclusion: Our meta-analysis supports a tailored diagnostic approach for MD, emphasizing the need for effective grading systems at each stage. For "Spotting," the model shows high specificity but requires improved sensitivity, suggesting additional criteria are needed. The "Confirming" stage highlights the need for refined, sensitive grading systems due to lower diagnostic accuracy. In the "Establishing" stage, an EH grade 1 threshold is effective, but grade 2 enhances sensitivity while reducing specificity, indicating a need for balance. The PLE grading system excels in sensitivity, making it highly reliable. High specificity in the normal ears subgroup confirms accurate non-pathological distinction, though Nakashima’s criteria show reduced sensitivity, underscoring variability in grading systems. These findings advocate for a standardized, unified grading system balancing sensitivity and specificity across all MD stages to optimize diagnostics and clinical outcomes.

18 December 2021 in Immunopathologia Persa
Verified
Journal Article
Open access
OYOmid Yazdani
Omid Yazdani
RFRamin Farahani
Ramin Farahani
RMReza Mosaed
Reza Mosaed
AAAmir Nezami Asl
Amir Nezami Asl
EHEbrahim Hazrati
Ebrahim Hazrati
Introduction: Adalimumab reduces the expression of the angiotensin-converting enzyme (ACE2) receptor at the cell surface, therefore it is thought to be effective in treating patients with COVID-19. Objectives: The present study was conducted to evaluate the effectiveness of adalimumab and pulsed corticosteroids in treating patients with severe acute respiratory failure due to COVID-19. Patients and Methods: The present double-blind clinical trial study was carried out on patients with COVID-19 referred to Imam Reza hospital, Tehran. Patients were randomly divided into two groups of intervention (patients under standard treatment according to the national protocol of Iran + methylprednisolone + adalimumab) and control (patients under standard treatment according to the national protocol of Iran + methylprednisolone). Results: The patients’ hospitalization information shows that the duration of patients’ hospitalization in the intervention group was significantly shorter than their counterparts in the control group (P=0.041). Serum levels of total bilirubin on the ninth day (P=0.043) and GCS (Glasgow coma scale) on the ninth day (P=0.041) and tenth (P=0.039) in the adalimumab group were significantly increased compared to the control group. However, the direct bilirubin value on the eighth day (P=0.031), serum creatinine on the 8th (P=0.047), 9th (P=0.047) and 10th (P=0.047) days and also PEEF (pericarditis/pericardial effusion) on the tenth day were significantly lower in the intervention group than the control group. Conclusion: The administration of adalimumab significantly increases the GCS of COVID-19 patients and reduces the length of hospital stay. Trial Registration: This study is designed as a double-blind clinical trial (identifier: IRCT20200406046963N2, https://www.irct.ir/trial/55011), and has been approved by the ethics committee in biomedical research of AJA University of Medical Sciences (#IR.AJAUMS.REC.1400.032).